StreetInsider.com News Articles

iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

Tue, 01 Sep 2026 16:30:00 -0400

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston.

Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will participate in a fireside chat on Tuesday, September 8, at 4:30 p.m. ET.

A livestream of the event can be accessed here, and a replay of the presentation webcast

iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

Tue, 01 Sep 2026 16:30:00 -0400

Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will participate in a fireside chat on Tuesday, September 8, at 4:30 p.m. ET.

A livestream of the event can be accessed here, and a replay of the presentation webcast

Form 10-K iBio, Inc. For: Jun 30

Fri, 28 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260828/26993379.html

Form 10-K iBio, Inc. For: Jun 30

Fri, 28 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260828/26993379.html

Form 8-K iBio, Inc. For: Aug 28

Fri, 28 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260828/26993364.html

Form 8-K iBio, Inc. For: Aug 28

Fri, 28 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260828/26993364.html

iBio posts $33M net loss in fiscal 2026 as R&D spending surges

Fri, 28 Aug 2026 07:02:09 -0400

iBio, Inc. (NASDAQ: IBIO) reported a net loss of $33.0 million for the fiscal year ended June 30, 2026, compared with a net loss of $18.4 million in the prior year, according to a company press release.

Revenue fell to approximately $0.1 million from $0.4 million in fiscal 2025. Research and development expenses rose to $19.6 million from $8.3 million, an increase of approximately $11.3 million, driven largely by spending on consultants and outside services for the IBIO-610 and IBIO-600 programs and a $2.5 million development milestone. General and administrative expenses were roughly flat at $10.6 million. The company also recorded

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Fri, 28 Aug 2026 07:00:00 -0400

SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress.

“Fiscal year 2026 was a transformative year for iBio, most importantly marked by our transition to a clinical-stage company with the initiation of the Phase 1 clinical trial of IBIO-600, a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Fri, 28 Aug 2026 07:00:00 -0400

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Fri, 28 Aug 2026 07:00:00 -0400

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Fri, 28 Aug 2026 07:00:00 -0400

Form PRE 14A iBio, Inc. For: Oct 14

Thu, 20 Aug 2026 06:59:00 -0400

si-local-file:///var/storage/secattach/20260820/26952557.html

Form PRE 14A iBio, Inc. For: Oct 14

Thu, 20 Aug 2026 06:59:00 -0400

si-local-file:///var/storage/secattach/20260820/26952557.html

Form SCHEDULE 13G iBio, Inc. Filed by: Lynx1 Capital Management LP

Fri, 14 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260814/26931890.html

Form SCHEDULE 13G iBio, Inc. Filed by: Lynx1 Capital Management LP

Fri, 14 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260814/26931890.html

Form SCHEDULE 13G/A iBio, Inc. Filed by: Vestal Point Capital, LP

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930339.html

Form SCHEDULE 13G/A iBio, Inc. Filed by: Vestal Point Capital, LP

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930339.html

Form SCHEDULE 13G/A iBio, Inc. Filed by: Cormorant Asset Management, LP

Fri, 14 Aug 2026 14:04:00 -0400

si-local-file:///var/storage/secattach/20260814/26928736.html

Form SCHEDULE 13G/A iBio, Inc. Filed by: Cormorant Asset Management, LP

Fri, 14 Aug 2026 14:04:00 -0400

si-local-file:///var/storage/secattach/20260814/26928736.html

Form SCHEDULE 13G/A iBio, Inc. Filed by: Affinity Asset Advisors, LLC

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920905.html

Form SCHEDULE 13G/A iBio, Inc. Filed by: Affinity Asset Advisors, LLC

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920905.html

Form 4 iBio, Inc. For: Jul 31 Filed by: Carr Molly

Tue, 04 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260804/26865885.html

Form 4 iBio, Inc. For: Jul 31 Filed by: Carr Molly

Tue, 04 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260804/26865885.html

Form 3 iBio, Inc. For: Jul 31 Filed by: Carr Molly

Tue, 04 Aug 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20260804/26861522.html

Form 3 iBio, Inc. For: Jul 31 Filed by: Carr Molly

Tue, 04 Aug 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20260804/26861522.html